TL;DR: A 2026 Nature Communications paper found that late-stage amyloid beta plaques in APP23 mice recruited CD8 T cells with a type I interferon program, linking Alzheimer-like amyloid pathology to a more adaptive immune response around plaques. Key Findings 21,156 immune cells profiled: The team used single-cell RNA and VDJ sequencing on CD45-positive brain immune …
TL;DR: A 2026 mouse study in Proceedings of the National Academy of Sciences found that deleting or inhibiting PTP1B improved memory behavior, reduced amyloid-beta burden, and pushed microglia toward an amyloid-clearing state. Key Findings Memory behavior improved: APP/PS1 mice lacking PTP1B performed better in novel object recognition and Morris water maze tests; the PTP1B inhibitor …
TL;DR: A 2026 medRxiv preprint applied the AT(N) framework, an Alzheimer’s disease biomarker system for amyloid, tau, and neurodegeneration, to 84 older adults with focal epilepsy and found that only 32.1% had normal blood biomarkers, while early-onset epilepsy carried higher odds of biomarker abnormality. Key Findings Epilepsy cohort: Researchers analyzed focal epilepsy participants from the …
TL;DR: A 2026 study in Microbiome found that in older adults at metabolic risk, virgin olive oil was linked to better cognitive preservation and richer gut microbiota, while common refined olive oil pointed the other way. Key Findings Metabolic-risk cohort tracked over time: The analysis followed 656 older adults who were 55-75 years old, cognitively …
TL;DR: A 2026 study in Cell Chemical Biology found that alzheimer’s inflammation may be driven by a specific chemical switch: S-nitrosylation of STING at cysteine 148, which pushed innate immune signaling toward synaptic damage. Key Findings STING carried the redox switch: The study identified S-nitrosylation of human STING at cysteine 148 as a redox modification …
TL;DR: A 2026 study in Neurology Open Access found that in 793 dementia-free adults, higher vitamin D levels around age 39 were associated with less tau readout on PET brain imaging about 16 years later, while amyloid beta did not show the same relationship. Key Findings 793 dementia-free adults: Participants had vitamin D measured in …
TL;DR: A 2026 study in Translational Psychiatry found that three different plasma p-tau217 assays separated Alzheimer’s dementia from controls and frontotemporal degeneration with excellent accuracy, shifting the test from whether the marker works to which platform clinics can deploy. Key Findings Three p-tau217 assays all performed strongly: The cohort included 39 cognitively unimpaired controls, 28 …
TL;DR: A 2026 study in Nature Communications found that self-administered finger-prick blood tests for phosphorylated tau 217 (p-tau217), an Alzheimer’s tau marker, and glial fibrillary acidic protein (GFAP), an astrocyte-injury marker, correlated with cognition and function in older adults. Key Findings Remote sampling: Participants used capillary finger-prick blood collection rather than standard clinic-based venous blood …
TL;DR: A 2026 study in Translational Neurodegeneration found that reducing NDST3, a microtubule deacetylase that affects lysosome acidity, restored lysosomal acidification and reduced amyloid-beta and tau pathology in Alzheimer’s cell and mouse models. Key Findings Lysosomal pH shifted back: APP695Swe-overexpressing HT22 cells had lysosomal pH near 5.6, while Ndst3 knockdown lowered it to less than …
TL;DR: A 2026 article-in-press study in Alzheimer’s Research & Therapy found that olfactory-region MRI radiomics, a method that turns brain scans into quantitative texture and shape features, linked blood pTau217, a tau-related Alzheimer’s disease biomarker, with cognitive impairment across three cohorts. Key Findings Three Alzheimer’s cohorts were matched: Researchers matched 122 Alzheimer’s disease (AD) patients …
